Lilly Sees Positive Results With Next-Gen Alzheimer’s Drug Donanemab

Patients Saw Less Cognitive, Functional Decline In Phase II Trial

 
• By Mandy Jackson
vector illustration of colorful brain
Donanemab also rapidly cleared amyloid from Alzheimer's patients' brains • Source: Shutterstock

More from Clinical Trials

More from R&D